DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yang, Seungju | ko |
dc.contributor.author | Im, San Hae | ko |
dc.contributor.author | Chung, Juyeon | ko |
dc.contributor.author | Lee, Juhee | ko |
dc.contributor.author | Lee, Kyung‐Hun | ko |
dc.contributor.author | Kang, Yoo Kyung | ko |
dc.contributor.author | Chung, Hyun Jung | ko |
dc.date.accessioned | 2024-05-20T08:00:09Z | - |
dc.date.available | 2024-05-20T08:00:09Z | - |
dc.date.created | 2024-05-20 | - |
dc.date.created | 2024-05-20 | - |
dc.date.issued | 2024-04 | - |
dc.identifier.citation | Advanced Science | - |
dc.identifier.uri | http://hdl.handle.net/10203/319413 | - |
dc.description.abstract | The CRISPR/Cas system has been introduced as an innovative tool for therapy, however achieving specific delivery to the target has been a major challenge. Here, an antibody-CRISPR/Cas conjugate platform that enables specific delivery and target gene editing in HER2-positive cancer is introduced. The CRISPR/Cas system by replacing specific residues of Cas9 with an unnatural amino acid is engineered, that can be complexed with a nanocarrier and bioorthogonally functionalized with a monoclonal antibody targeting HER2. The resultant antibody-conjugated CRISPR/Cas nanocomplexes can be specifically delivered and induce gene editing in HER2-positive cancer cells in vitro. It is demonstrated that the in vivo delivery of the antibody-CRISPR/Cas nanocomplexes can effectively disrupt the plk1 gene in HER2-positive ovarian cancer, resulting in substantial suppression of tumor growth. The current study presents a useful therapeutic platform for antibody-mediated delivery of CRISPR/Cas for the treatment of various cancers and genetic diseases. | - |
dc.language | English | - |
dc.publisher | Wiley | - |
dc.title | An Antibody‐CRISPR/Cas Conjugate Platform for Target‐Specific Delivery and Gene Editing in Cancer | - |
dc.type | Article | - |
dc.identifier.wosid | 001193245900001 | - |
dc.identifier.scopusid | 2-s2.0-85188915069 | - |
dc.type.rims | ART | - |
dc.citation.publicationname | Advanced Science | - |
dc.identifier.doi | 10.1002/advs.202308763 | - |
dc.contributor.localauthor | Chung, Hyun Jung | - |
dc.contributor.nonIdAuthor | Lee, Kyung‐Hun | - |
dc.contributor.nonIdAuthor | Kang, Yoo Kyung | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article; Early Access | - |
dc.subject.keywordPlus | antibody conjugation | - |
dc.subject.keywordPlus | cancer therapy | - |
dc.subject.keywordPlus | CRISPR/Cas | - |
dc.subject.keywordPlus | in vivo gene editing | - |
dc.subject.keywordPlus | specific delivery | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.